Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ReminX is a digital health company that provides a personalized reminiscence therapy platform designed for individuals with Alzheimer's disease and other forms of dementia. The company's mobile application allows family members and caregivers to create stories using personal photos and voice narrations, which are delivered to the patient via a simplified interface. This non-pharmacological intervention aims to reduce behavioral symptoms such as agitation and anxiety while fostering social connection. ReminX serves both individual families and senior living communities, positioning itself as a scalable solution for memory care. The company was co-founded by Dr. Michael Weiner, a leading researcher in Alzheimer's disease, ensuring the platform is grounded in clinical evidence.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ReminX.